-
At the end of the year, a batch of pharmaceutical equipment companies actively recruited people. What signal did they release behind?
Time of Update: 2021-12-29
(Image source: Pharmaceutical Network) According to a search on a talent recruitment website, the author learned that since November, Chutian Technology is hiring sales managers (nationally stationed), sales managers in India and other positions; Teflon is also posting a number of recruitments recently information, recruitment positions, including sales manager, international marketing specialist, director of international recruitment / High Commissioner, the international business development manager, international service engineers .
-
CDE releases 2 technical guidelines for clinical trials involving weight control and advanced prostate cancer
Time of Update: 2021-12-29
Attachment: Notice on Technical Guidelines for Clinical Trials of Weight Control Drugs Regarding the Public Solicitation of "Technical Guidelines for Endpoints for Advanced Prostate Cancer Clinical Trials (Draft for Comment)" Prostate cancer is a common urinary system malignant tumor, which is unique compared to other solid tumors The characteristics of the disease, such as different disease stages according to the sensitivity to androgen deprivation treatment and whether it has metastasis, high incidence of bone metastasis and serum biomarker PSA, etc.
-
At the end of the year, the personnel adjustment of multinational pharmaceutical companies has accelerated!
Time of Update: 2021-12-29
It is understood that after the release of the sixth batch of special insulin procurement results, the adjustment of personnel from many multinational pharmaceutical companies involved in the centralized procurement including Novo Nordisk and Sanofi has been accelerated .
-
Asia-Pacific Pharmaceuticals Receives Acceptance Notice for Consistency Evaluation of Terazosin Hydrochloride Tablets
Time of Update: 2021-12-29
On December 9, Asia-Pacific Pharmaceuticals issued an announcement stating that it had recently received an acceptance notice on the consistency evaluation of terazosin hydrochloride tablets issued by the National Medical Products Administration .
Oral administration of terazosin hydrochloride tablets is also suitable for the treatment of symptoms caused by benign prostatic hyperplasia (BPH) .
-
Two major pharmaceutical companies join hands to jointly carry out clinical trials of drugs under research for peritoneal cancer
Time of Update: 2021-12-29
The agreement stipulates that the two parties will jointly evaluate Shamrock Bio's recombinant human TRAIL-trimer fusion protein (SCB-313) and the SMAC mimic/inhibitor of apoptosis protein (IAP) targeted therapy small molecule antagonist ( APG-1387), the effect of combined treatment of advanced peritoneal cancer in phase 1b/2 clinical trials .
-
First-line treatment for nasopharyngeal cancer BeiGene PD-1 inhibitor combination significantly prolongs PFS in patients
Time of Update: 2021-12-29
On December 10, 2021, BeiGene announced that the anti-PD-1 antibody tislelizumab combined with chemotherapy, a phase 3 clinical trial for the first-line treatment of patients with recurrent/metastatic nasopharyngeal carcinoma reached the primary endpoint .
-
Implementation Rules for the Management of Chinese Medicine Formula Granules in Fujian Province Issued
Time of Update: 2021-12-29
(Chen Siyuan) A few days ago, the Fujian Provincial Food and Drug Administration, the Provincial Health Commission, and the Provincial Medical Insurance Bureau jointly issued the "Implementation Rules for the Management of Chinese Medicine Formula Granules in Fujian Province (Trial)" (hereinafter referred to as the "Detailed Rules") to further standardize and strengthen the management of Fujian Province Chinese Medicine Formula Granules .
-
The State Food and Drug Administration held a seminar on the supervision of online sales of medical devices
Time of Update: 2021-12-29
On December 9, the State Food and Drug Administration held a medical device online sales supervision work exchange meeting to implement the "Medical Device Supervision and Administration Regulations"
-
Promoting the development of the pharmaceutical industry has become an important task for all regions
Time of Update: 2021-12-29
The industry believes that the release of this policy will continue to promote the development of innovative drugs in Daxing District and accelerate the technological innovation of the medical device industry, and undertake the achievements of Beijing and global scientific and technological innovations, continue to attract domestic and international high-quality resources, and achieve a high-quality cluster of the pharmaceutical and health industry in Daxing District Style development .
-
The first in China!
Time of Update: 2021-12-29
CCR8 small molecule inhibitors can not only inhibit tumor cell metastasis, but also inhibit tumor-associated Treg cells (Treg II) infiltration into tumor tissues, thereby reversing the tumor immunosuppressive microenvironment and enhancing the anti-tumor immune response .
-
Sino Medical's new class of drug-eluting stent system application for pre-market approval in the United States is accepted
Time of Update: 2021-12-29
On December 9, Sino Medical issued an announcement stating that in December 2021, it had submitted the final application for the company’s new type of healing-oriented drug-eluting stent system (trade name: HT Supreme) to the U.
The company’s new drug-eluting stent system was officially accepted by the FDA and entered the final pre-market approval (PMA) review process .
-
In rushing to the "last train" of 2021, the chairman of two pharmaceutical companies resigned!
Time of Update: 2021-12-29
Chairman of China Resources Sanjiu resigns On December 3, China Resources Sanjiu issued an announcement stating that the board of directors received a resignation report from Chairman Wang Chuncheng.
The current deputy general manager of China Resources Group and the chairman of the board of directors of China Resources Pharmaceutical Group Co.
-
CDE publicly solicits opinions on "Technical Guidelines for Clinical Evaluation of Intravenous Anesthetics"
Time of Update: 2021-12-29
On December 7, CDE issued the "Technical Guidelines for the Clinical Evaluation of Intravenous Anesthetics" for soliciting comments.
The time limit for soliciting opinions is 1 month from the date of publication .
"Technical Guidelines for Clinical Evaluation of Intravenous Anesthetics (Draft for Comment)" Feedback Form 3.
-
In 2022, what are the new technological directions of the innovative drug track worth paying attention to?
Time of Update: 2021-12-29
Small nucleic acid drugs, or RNAi technology drugs, are currently the focus of research in the industry.
It is understood that the key technology for the development of small nucleic acid interference therapy mainly lies in delivery technology and RNAi molecular design.
-
Cooperation between pharmaceutical companies and AI companies has become a general trend in the industry, and innovations may accelerate
Time of Update: 2021-12-29
In addition to Hengrui Medicine, in September this year, Jingxin Pharmaceutical and AI drug research and development company Jingtai Technology also reached a project cooperation to jointly promote the research and development of small molecule antidepressant drugs .
-
New indication of Haisco's "Cycloprofen" approved
Time of Update: 2021-12-29
According to the Insight database, Haisco has currently initiated 6 phase 3 clinical trials for cycloporol, 5 of which have been completed, which most likely corresponds to the 5 indications declared by it .
-
Hengrui Medicine's PD-1 Inhibitor Carrelizumab Approved for New Indication
Time of Update: 2021-12-29
On December 10, China's National Food and Drug Administration (NMPA) recently announced that Hengrui Medicine's PD-1 inhibitor carrelizumab has been approved for the marketing of two new indications .
-
Industry recommendations: Layout of pharmaceutical manufacturing upgrades in 2022, focusing on the upstream of biomedicine
Time of Update: 2021-12-29
The industry predicts that in the future, domestic biopharmaceutical equipment companies such as Dongflon and Chutian Technology are expected to accelerate the pace of import substitution and achieve new growth .
-
In the past week, more than 16 biomedical companies have been investigated by institutions!
Time of Update: 2021-12-29
According to statistics, in the past week (December 1st to December 7th), at least 16 biomedical companies have been investigated by institutions, including Corfu Medical, Jincheng Pharmaceutical, Robust Medical, Xianju Pharmaceutical, Jincheng Pharmaceutical, and Panlong Pharmaceuticals, Yuekang Pharmaceuticals, etc.
-
More than 30 pharmaceutical companies will be listed on the Sci-tech Innovation Board by 2021, and the market value of four will exceed 30 billion yuan
Time of Update: 2021-12-29
187 billion yuan Chengda Biologics was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on October 28, 2021, and its current new market value is 32.
